ID   11-18-ER2-1
AC   CVCL_D857
SY   11-18/ER2-1
DR   cancercelllines; CVCL_D857
DR   Cosmic; 1731374
DR   Wikidata; Q54554909
RX   PubMed=22815900;
CC   Population: Japanese and Micro.
CC   Selected for resistance to: ChEBI; CHEBI_114785; Erlotinib.
CC   Sequence variation: Mutation; HGNC; HGNC:3236; EGFR; Simple; p.Leu858Arg (c.2573T>G); ClinVar=VCV000016609; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Lung; UBERON=UBERON_0002048.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_6659 ! 11-18
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 19-12-24; Version: 17
//
RX   PubMed=22815900; DOI=10.1371/journal.pone.0041017; PMCID=PMC3398867;
RA   Tabara K., Kanda R., Sonoda K., Kubo T., Murakami Y., Kawahara A.,
RA   Azuma K., Abe H., Kage M., Yoshinaga A., Tahira T., Hayashi K.,
RA   Arao T., Nishio K., Rosell R., Kuwano M., Ono M.;
RT   "Loss of activating EGFR mutant gene contributes to acquired
RT   resistance to EGFR tyrosine kinase inhibitors in lung cancer cells.";
RL   PLoS ONE 7:E41017-E41017(2012).
//